| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 04/28/2005 | US20050089960 Biosynthesis; immunoglobulin signal peptides; fusion proteins; for delivery to the central nervous system and eye by gene therapy; host cells |
| 04/28/2005 | US20050089941 Drug screening; SCFV fragments; polyacrylamide gel electrophoresis |
| 04/28/2005 | US20050089922 Inhibiting nucleic acid synthesis, comprising a nucleic acid inhibitor that is capable of binding or has affinity to an enzyme with polymerase activity; an oligonucliotide inhibiting or preventing nucleic acid synthesis, amplification or sequencing; polymerase inhibitors; viricides; HIV |
| 04/28/2005 | US20050089917 Novel kinases and uses thereof |
| 04/28/2005 | US20050089911 87 human secreted proteins |
| 04/28/2005 | US20050089896 Method to control tumor progression and invasiveness |
| 04/28/2005 | US20050089892 Biiodrugs for diagnosis, drug screening, clinical trial monitoring, treatment of physiological disorders; viral disease and infection prevention; expression vectors |
| 04/28/2005 | US20050089887 Novel human ion channel proteins |
| 04/28/2005 | US20050089868 Modulators of tissue regeneration |
| 04/28/2005 | US20050089866 Identifying modulators for the treatment and prevention of diabetes, pain, obesity, nervous system, inflammatory, cell proliferative and liver disorders |
| 04/28/2005 | US20050089858 Expression vector comprising nucleotide sequences coding tumor suppressor protein for use in diagnosis and prevention of cell proliferative disorders |
| 04/28/2005 | US20050089844 Novel dual oxidases as mitogenic and endocrine regulators |
| 04/28/2005 | US20050089531 Two types of foreign genes inserted in such a manner as to allow the expression into two different regions in the recombinant feline herpesvirus type 1 genome |
| 04/28/2005 | US20050089513 A side population cell separated from human amniotic mesenchymal cell layer, in which expressions of Oct-4 gene, Sox-2 gene and Rex-I gene are observed by RT-PCR, and which is vimentin-positive and CK19-positive in immunocytostaining; useful for therapies of metabolic diseases such as lysosomal disease |
| 04/28/2005 | US20050089511 Methods and compositions comprising DNA damaging agents and p53 |
| 04/28/2005 | US20050089493 Spermine peptide surfactants with amide or amine bonds for surfactants used to transfer cells |
| 04/28/2005 | CA2548551A1 Shc proteins as therapeutic targets in proliferative diseases |
| 04/28/2005 | CA2543406A1 Mutants of human chondromodulin-i (hchm-i) and uses thereof in inhibiting angiogenesis and bone resorption |
| 04/28/2005 | CA2542765A1 Method of inhibiting secretase activity |
| 04/28/2005 | CA2542631A1 Listeria-based epha2 vaccines |
| 04/28/2005 | CA2542417A1 Methods and compositions for the treatment of neurological disease |
| 04/28/2005 | CA2542337A1 Cancer gene therapeutic drug |
| 04/28/2005 | CA2542335A1 Cancer gene therapeutic drug |
| 04/28/2005 | CA2526691A1 High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens |
| 04/27/2005 | EP1526184A1 Promoter sequences specific for cells of the B lymphoid lineage and pharmaceutical compositions containing the same |
| 04/27/2005 | EP1526183A2 Dimer of a peptide derived from the C-terminal sequence of human superoxide dismutase facilitating the penetration of a substance into cells and/or cell nuclei |
| 04/27/2005 | EP1526174A2 Compositions comprising viruses and methods for concentrating virus preparations |
| 04/27/2005 | EP1526173A2 Compositions comprising viruses and methods for concentrating virus preparations |
| 04/27/2005 | EP1526141A2 MHC complexes and uses thereof |
| 04/27/2005 | EP1525881A2 Integrative protein-DNA cochleate fomulations and methods for transforming cells |
| 04/27/2005 | EP1525323A2 Pgc-beta, a novel pgc-1 homologue and uses therefor |
| 04/27/2005 | EP1525312A2 Brachyspira hyodysenteriae vaccine |
| 04/27/2005 | EP1525308A2 Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
| 04/27/2005 | EP1525224A1 Hyaluronic acid derivatives |
| 04/27/2005 | EP1525000A2 Gastrointestinal delivery of genetic material coupled to a transporting agent |
| 04/27/2005 | EP1524977A2 Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy |
| 04/27/2005 | EP1524974A2 Transcription factor modulating compounds and methods of use thereof |
| 04/27/2005 | EP1150707B1 USE OF AN OmpA ENTEROBACTERIUM PROTEIN ASSOCIATED WITH THE ELAGIGILTV PEPTIDE FOR TREATING MELANOMAS |
| 04/27/2005 | EP0939818B1 Recombinant toxin fragments |
| 04/27/2005 | EP0935470B1 Method for treating allergic lung disease |
| 04/27/2005 | CN1610743A Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 04/27/2005 | CN1610556A Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen |
| 04/27/2005 | CN1610502A Surfactant protein for the prevention and diagnosis of pulmonary emphysema |
| 04/27/2005 | CN1609224A Recombinant glandular associated virus expression vector carrying alpha-melanophore stimulin gene and its use |
| 04/27/2005 | CN1609213A Gene cloning of polyepitope antigen of hepatitis C virus and its coding sequence |
| 04/27/2005 | CN1608677A Stem cell target-locating and enriching method |
| 04/27/2005 | CN1608676A Orally taken carrier to transduce liver and intestine cell |
| 04/27/2005 | CN1608675A Medicine-carrying nanometer polymer particle and its prepn and use |
| 04/27/2005 | CN1198934C RNA virus vector having contact infiltration capability |
| 04/27/2005 | CN1198932C Streptococcus pneumoniae antigens |
| 04/27/2005 | CN1198931C MOraxella catarrhalis BASB034 polypeptides and uses thereof |
| 04/27/2005 | CN1198640C Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 04/27/2005 | CN1198589C Method for controlling liposome size |
| 04/26/2005 | US6884871 Isolation and use of tissue growth-inducing Frzb protein |
| 04/26/2005 | US6884785 Compositions and methods for the treatment or prevention of autoimmune diabetes |
| 04/26/2005 | US6884779 Hybrid screening analyzing |
| 04/26/2005 | US6884770 Prophylaxis of nerve system disorders comprising administering to animals hedgehog proteins having amino acid sequences that bind to receptors and promote hedgehog signal transduction |
| 04/26/2005 | US6884619 Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors |
| 04/26/2005 | US6884617 Comprises nucleotide sequences coding myogenic factors for diagnosis and treatment of cell proliferative and muscular disorders |
| 04/26/2005 | US6884613 Purification of preferential viral particles; obtain solution containing viral particles, mix with polyelectrolyte, centrifuge, recover pellet, separate viral particles from pellet |
| 04/26/2005 | US6884594 Antibodies to growth factor HTTER36 |
| 04/26/2005 | US6884585 Induction of beta cell differentiation in human cells by stimulation of the GLP-1 receptor |
| 04/26/2005 | US6884576 Genetically engineered cell for use in the diagnosis, prevntion and treatment of viral diseases |
| 04/26/2005 | US6884431 Method for treating proliferative diseases with p27 and fusions thereof |
| 04/26/2005 | US6884430 Formulation of stabilized cationic transfection agent(s) /nucleic acid particles |
| 04/26/2005 | CA2253871C Ret ligand (retl) for stimulating neural and renal growth |
| 04/26/2005 | CA2152505C Method for preparing a viral aerosol |
| 04/21/2005 | WO2005035779A2 Method |
| 04/21/2005 | WO2005035772A1 Simplified method for producing therapeutic viral vectors which are free of marker genes in their therapeutically suitable form |
| 04/21/2005 | WO2005035771A2 Nucleic acid constructs |
| 04/21/2005 | WO2005035765A1 Method of inhibiting interferon response |
| 04/21/2005 | WO2005035764A1 Autogene nucleic acids encoding a secretable rna polymerase |
| 04/21/2005 | WO2005035746A2 Medical use of tbk-1 or of inhibitors thereof |
| 04/21/2005 | WO2005035550A2 Dual phase-pna conjugates for the delivery of pna through the blood brain barrier |
| 04/21/2005 | WO2005034984A1 Cd44 splice variant in diagnosis and therapy of intestinal cancer |
| 04/21/2005 | WO2005034978A2 MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF |
| 04/21/2005 | WO2004108940A3 Viral genome vectors |
| 04/21/2005 | WO2004104199A3 Modulation of gene expression using dna-dna hybrids |
| 04/21/2005 | WO2004098490A3 Mesoderm and definitive endoderm cell populations |
| 04/21/2005 | WO2004090112B1 Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction |
| 04/21/2005 | WO2004089423A3 Pharmico-gene theraphy of epithelial sodium channel associated disoders |
| 04/21/2005 | WO2004078942A3 Endothelial cell specific antibodies and uses thereof |
| 04/21/2005 | WO2004069992A3 Oligomeric compounds for the modulation of ras expression |
| 04/21/2005 | WO2004056080A9 Endothelial cell specifically binding peptides |
| 04/21/2005 | WO2004045543A3 Functional and hyperfunctional sirna |
| 04/21/2005 | WO2004041156A3 Method for determining sensitivity to a bacteriophage |
| 04/21/2005 | WO2004009802A3 gM-NEGATIVE EHV-MUTANTS WITHOUT HETEROLOGOUS ELEMENTS |
| 04/21/2005 | WO2003105753A3 Targeted enzymes and methods of making and using targeted enzymes. |
| 04/21/2005 | WO2003070189A3 Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein |
| 04/21/2005 | WO2003069311A3 Methods and compositions for use in spliceosome mediated rna trans-splicing |
| 04/21/2005 | WO2003040330A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 04/21/2005 | WO2002099053A3 Slc22as as modifiers of the p53 pathway and methods of use |
| 04/21/2005 | WO2002092842A3 Nucleic acids and corresponsing proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer |
| 04/21/2005 | WO2002092841A3 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
| 04/21/2005 | US20050085711 Method and system for leading macromolecule substances into living target cells |
| 04/21/2005 | US20050085627 Nucleotide sequences coding histone methyltransferase for use in identifying modulators for treatment and prevention of asthma disorders |
| 04/21/2005 | US20050085486 Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases |
| 04/21/2005 | US20050085435 Novel inhibitors of poxvirus replication |
| 04/21/2005 | US20050085434 Ballast administering to human skins; dna vaccine; high density core overcoated with amorphous reservoir containing dna |
| 04/21/2005 | US20050085411 A peptidomimetic as an antiproliferative agent |